Latest Australian Markets News

Peet Limited has reported a robust half-year performance with statutory profit doubling and a significant dividend increase, underpinned by strong sales and settlements across key Australian markets.

Marimaca Copper has successfully raised C$409 million through a dual Canadian and Australian equity offering, positioning the company to advance its flagship Marimaca Project and exploration at Pampa Medina.

NAOS Emerging Opportunities Company Limited has reported a robust half-year profit increase of 103%, alongside a fully franked interim dividend of 2.10 cents per share, reflecting strong portfolio performance and market confidence.

NAOS Small Cap Opportunities Company Limited reported a remarkable half-year profit surge and declared a steady quarterly dividend, despite portfolio returns lagging the benchmark index.

Solvar Limited reported a 5.8% rise in net profit for the half year ending December 2025, driven by strategic asset sales and expanded funding facilities. The company declared both interim and special dividends, signalling confidence despite ongoing regulatory challenges.

Dexus has reported a strong half-year result with a $348.5 million profit turnaround, robust leasing growth, and strategic capital moves including a $950 million equity raise and a 10% on-market buyback.

Pureprofile Limited has agreed to acquire CRNRSTONE, an established Australian qualitative research firm, for $700,000 in cash, enhancing its market research capabilities and expected to be earnings accretive from year one.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

Dusk Group Limited reported a solid first half of FY26 with total sales rising 5.1% to $91.8 million, underpinned by product innovation and a successful AfterGlow store format trial. The company also announced a fully franked interim dividend of 4.0 cents per share.

Centuria Industrial REIT (ASX – CIP) reported a robust HY26 with strong income growth, portfolio valuation gains, and an upgraded full-year earnings forecast, underpinned by active leasing and strategic capital management.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

TradeWindow reports solid growth in recurring revenue and average revenue per customer but lowers its FY26 trading revenue guidance due to softer transactional volumes in Q3.